TB-500 and the July 2026 FDA Panel: What It Means
TB-500, a synthetic version of Thymosin Beta-4, was reviewed by the FDA’s Pharmacy Compounding Advisory Committee on July 23, 2026. The panel voted 8–6 to recommend it, against FDA staff advice.
News
-
-
KPV and Gut Inflammation Research: What Studies Show
KPV (Lys-Pro-Val) is a naturally occurring tripeptide derived from the C-terminus of alpha-melanocyte-stimulating hormone (alpha-MSH). Research has focused on its anti-inflammatory activity in gut epithelial cells, particularly its ability to inhibit NF-κB signaling without the systemic effects associated with full-length alpha-MSH.
-
GHK-Cu in Skin Research: What the Evidence Shows
GHK-Cu (glycyl-L-histidyl-L-lysine copper complex) has been studied extensively for its role in collagen and glycosaminoglycan synthesis, antioxidant gene expression, and skin barrier repair. It is one of the highest-volume compounds in the cosmetic research segment and among the most cited peptides in dermatological literature.
-
NAD+ and Cellular Aging: The 2026 Research Picture
NAD+ (nicotinamide adenine dinucleotide) has emerged as one of the most studied molecules in longevity research. As a co-substrate for more than 500 enzymes, it plays a central role in DNA repair, mitochondrial function, and sirtuin activation — all key pathways in the biology of aging.
-
Retatrutide: How a Triple-Agonist Peptide Works
Retatrutide is a synthetic peptide that simultaneously activates three metabolic hormone receptors: GLP-1, GIP, and glucagon. This triple agonist mechanism distinguishes it from earlier generation GLP-1 analogues and has made it a subject of significant research interest in metabolic biology.